Read the latest issue of our News from ECOG-ACRIN blog
Cancer doesn’t stop for COVID, and neither should cancer screening or treatment Advocacy Blog
Our clinical trials are enrolling patients during the pandemic More Here
Question about COVID19? Send an email
Practice-changing trial results for advanced melanoma skin cancer are being reported today at the Inaugural ASCO Plenary Series by study chair Michael Atkins, MD (Georgetown Lombardi Comprehensive Cancer Center). Starting treatment with immunotherapy then giving targeted therapy if the disease progressed led to a significant increase in two-year survival in the DREAMseq phase 3 trial for patients with BRAF V600 mutant metastatic melanoma. November 16, 2021 Press Release
Mitchell D. Schnall, MD, PhD (University of Pennsylvania), was re-elected as the Group Co-Chair, a position he has held since the founding of the ECOG-ACRIN Cancer Research Group in 2012. Dr. Schnall will continue to ensure the effective integration of radiology research with medical oncology and other disciplines involved in cancer research. Read More
Amidst the ongoing COVID-19 pandemic, the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) continues to post strong monthly accrual. Read more.
Adjuvant therapy with sunitinib or sorafenib did not improve disease-free survival or overall survival in patients with sarcomatoid renal cell carcinoma, according to a post hoc analysis from study E2805 by Jose A. Karam, MD, FACS, and colleagues. September 4, 2021. British Journal of Urology International
Entinostat does not overcome endocrine resistance in advanced breast cancer, as Roisin Connolly and colleagues report in the final results of the E2112 trial. August 17, 2021. Cancer Therapy Advisor
Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.
The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.
We look forward to sharing our research and partnering with you, as we reshape the future of patient care.
Robert L. Comis, MD